Please login (Members) to view content or
(Nonmembers) this article.
No votes yet
Oncology Update

Oncology Update

Diane M. Otte
ONF 2012, 39(5), 507-508 DOI: 10.1188/12.ONF.507-508

In a poster discussion session at the American Society of Clinical Oncology meeting in Chicago, IL, Daniel George, MD, of Duke University Medical Center discussed updated results from a phase II study of orteronel, a selective oral 17,20-lyase inhibitor dosed without prednisone in patients with nonmetastatic castrate-resistant prostate cancer and rising prostate-specific antigen (PSA). The primary objective of the study was to determine the percentage of patients achieving a PSA reduction to 0.2 ng/ml or less (undetectable levels) after three months. The study included 39 patients and showed the following results.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or